


Insulin-Like Growth Factor-I Update

Effective Date: January 3, 2017

Commencing January 3, 2017, Beaumont Laboratory will be implementing a re-standardized Insulin-Like Growth Factor-1 (IGF-1) assay on the Siemens Immulite 2000/XPi platform. The re-standardized assay is expected to produce **lower** IGF-1 values compared to the current assay, as demonstrated below in the bias plots from our internal studies.



KEY ASSAY FEATURES

- New age and gender-specific reference ranges as specified in the Lab Test Directory at: <http://beaumontlaboratory.com/test-lab-directory>
- Due to the lower IGF-1 values expected with the re-standardized assay, it is warranted to re-baseline patients being monitored for growth disorders. We apologize for the inconvenience this may cause to you and your patients.

If you have questions, please contact Client Services (1-800-551-0488, option 5).

Date submitted: December 13, 2016

Submitted By: Gabriel Maine, PhD
Technical Director, Royal Oak Special Testing Laboratory
Elizabeth Sykes, MD
Medical Director, Royal Oak Special Testing Laboratory

Beaumont Laboratory
Customer Service
1-800-551-0488